Zobrazeno 1 - 10
of 666
pro vyhledávání: ''
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Background There is a growing concern that the use of anti-hypertensives may be associated with an increased risk of cancer, but it remains uncertain for the association between anti-hypertensives and lung cancer risk, as well as their interaction wi
Publikováno v:
BMC Endocrine Disorders
BMC Endocrine Disorders, Vol 21, Iss 1, Pp 1-17 (2021)
BMC Endocrine Disorders, Vol 21, Iss 1, Pp 1-17 (2021)
Background Prolactinoma is a functional pituitary adenoma that secretes excessive prolactin. Dopamine agonists (DAs) such as bromocriptine (BRC) are the first-line treatment for prolactinomas, but the resistance rate is increasing year by year, creat
Autor:
Manran Liu, Yixuan Hou, Pengpeng Zhu, Liping Yang, Xueying Wan, Rui Wang, Yongcan Liu, Yong Teng, Yan Sun, Yilu Qin, Shuiqing Liu
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-23 (2021)
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-23 (2021)
BackgroundCancer stem cells (CSCs) are considered as the major cause to tumor initiation, recurrence, metastasis, and drug resistance, driving poor clinical outcomes in patients. Long noncoding RNAs (lncRNAs) have emerged as crucial regulators in can
Autor:
F. J. Hinsenveld, Bo Jan Noordman, Daniela E. Oprea-Lager, G J L H van Leenders, S. C. van Beek, S. L. van der Pas, Joost L. Boormans, André N. Vis, Jens Voortman
Publikováno v:
BMC Cancer
BMC Cancer, 21(1):1161. BioMed Central Ltd.
BMC Cancer, 21(1):1161. BioMed Central
Hinsenveld, F J, Noordman, B J, Boormans, J L, Voortman, J, van Leenders, G J L H, van der Pas, S L, van Beek, S C, Oprea-Lager, D E & Vis, A N 2021, ' Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer : the PRE-PREVENCYS trial ', BMC Cancer, vol. 21, no. 1, 1161, pp. 1161 . https://doi.org/10.1186/s12885-021-08840-2, https://doi.org/10.1186/s12885-021-08840-2
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
BMC Cancer, 21(1):1161. BioMed Central Ltd.
BMC Cancer, 21(1):1161. BioMed Central
Hinsenveld, F J, Noordman, B J, Boormans, J L, Voortman, J, van Leenders, G J L H, van der Pas, S L, van Beek, S C, Oprea-Lager, D E & Vis, A N 2021, ' Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer : the PRE-PREVENCYS trial ', BMC Cancer, vol. 21, no. 1, 1161, pp. 1161 . https://doi.org/10.1186/s12885-021-08840-2, https://doi.org/10.1186/s12885-021-08840-2
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Background The recommended treatment for patients with non-metastatic muscle-invasive bladder cancer (MIBC) is neoadjuvant chemotherapy (NAC) and radical cystectomy (RC). Following NAC, 20–40% of patients experience a complete pathological response
Autor:
The OpenSAFELY Collaborative, Angel Y. S. Wong, Laurie A. Tomlinson, Jeremy P. Brown, William Elson, Alex J. Walker, Anna Schultze, Caroline E. Morton, David Evans, Peter Inglesby, Brian MacKenna, Krishnan Bhaskaran, Christopher T. Rentsch, Emma Powell, Elizabeth Williamson, Richard Croker, Seb Bacon, William Hulme, Chris Bates, Helen J. Curtis, Amir Mehrkar, Jonathan Cockburn, Helen I. McDonald, Rohini Mathur, Kevin Wing, Harriet Forbes, Rosalind M. Eggo, Stephen J. W. Evans, Liam Smeeth, Ben Goldacre, Ian J. Douglas
Publikováno v:
Journal of Hematology & Oncology
Wong, A Y S, Tomlinson, L A, Brown, J P, Elson, W, Walker, A J, Schultze, A, Morton, C E, Evans, D, Inglesby, P, MacKenna, B, Bhaskaran, K, Rentsch, C T, Powell, E, Williamson, E, Croker, R, Bacon, S, Hulme, W, Bates, C, Curtis, H J, Mehrkar, A, Cockburn, J, McDonald, H I, Mathur, R, Wing, K, Forbes, H, Eggo, R M, Evans, S J W, Smeeth, L & Goldacre, B & Douglas, I J 2021, ' Association between warfarin and COVID-19-related outcomes compared with direct oral anticoagulants : population-based cohort study ', Journal of Hematology and Oncology, vol. 14, no. 1, 172 . https://doi.org/10.1186/s13045-021-01185-0
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-10 (2021)
Wong, A Y S, Tomlinson, L A, Brown, J P, Elson, W, Walker, A J, Schultze, A, Morton, C E, Evans, D, Inglesby, P, MacKenna, B, Bhaskaran, K, Rentsch, C T, Powell, E, Williamson, E, Croker, R, Bacon, S, Hulme, W, Bates, C, Curtis, H J, Mehrkar, A, Cockburn, J, McDonald, H I, Mathur, R, Wing, K, Forbes, H, Eggo, R M, Evans, S J W, Smeeth, L & Goldacre, B & Douglas, I J 2021, ' Association between warfarin and COVID-19-related outcomes compared with direct oral anticoagulants : population-based cohort study ', Journal of Hematology and Oncology, vol. 14, no. 1, 172 . https://doi.org/10.1186/s13045-021-01185-0
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-10 (2021)
Background Thromboembolism has been reported as a consequence of severe COVID-19. Although warfarin is a commonly used anticoagulant, it acts by antagonising vitamin K, which is low in patients with severe COVID-19. To date, the clinical evidence on
Autor:
Dehui Zou, Ru Feng, Haiyan Yang, Zhiyue Huang, Jianda Hu, David Simpson, Huilai Zhang, Yongping Song, Daobin Zhou, Sujun Gao, Huafei Lu, Wei Xu, Jianfeng Zhou, Yuqin Song, Keshu Zhou, Jie Jin, Stephen Opat, Tycel Phillips, Jie Ji, Michael Wang, Constantine S. Tam, Fangfang Lv
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-4 (2021)
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-4 (2021)
Mantle cell lymphoma (MCL) is a mature B-cell neoplasm with a high initial response rate followed almost invariably by relapse. Here we report the pooled data from 2 studies, BGB-3111-AU-003 and BGB-3111-206, to explore the efficacy of zanubrutinib m
Autor:
Xiaolin Guan, Yanchun Wang, Lin Guo, Keyu Zhu, Hui Zheng, Yixuan Liu, Renquan Lu, Suhong Xie, Ying Tong
Publikováno v:
Journal of Ovarian Research
Journal of Ovarian Research, Vol 14, Iss 1, Pp 1-10 (2021)
Journal of Ovarian Research, Vol 14, Iss 1, Pp 1-10 (2021)
Background Drug resistance and recurrence are main contributors to the poor prognosis of ovarian cancer. Cisplatin is a platinum compound which is widely used in the treatment of various solid tumors including ovarian cancer. Up to now, the mechanism
Autor:
Sharon Shacham, Jatin P. Shah, Robert F. Cornell, Ajay K. Nooka, Noa Biran, Paul G. Richardson, Mohamad Mohty, Terri L. Parker, Frenzel Laurent, Lingling Li, Monika Engelhardt, David Kaminetzky, Nathalie Meuleman, Thierry Facon, Jagannath Sundar, Joshua Richter, Gabriel Tremblay, Chantal Doyen, David S. Siegel, Martin Schreder, Philip Vlummens, Maria Gavriatopoulou, Michel Delforge, Marc S. Raab, Katja Weisel, Klaus Podar, Luciano J. Costa, Karlin Lionel, Dan T. Vogl, Philippe Moreau, Ravi Vij, David Dingli, Sascha A. Tuchman, Sylvain Choquet, Meletios-Athanasios Dimopoulos, Janis L. Breeze, Gary J. Schiller, James E. Hoffman, Michael Kauffman, Moshe Yair Levy, Patrick Daniele, Ajaj Chari
Publikováno v:
BMC Cancer
BMC CANCER
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
BMC CANCER
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Background Selinexor is an oral, selective nuclear export inhibitor. STORM was a phase 2b, single-arm, open-label, multicenter trial of selinexor with low dose dexamethasone in patients with penta-exposed relapsed/refractory multiple myeloma (RRMM) t
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
Background Nasopharyngeal carcinoma (NPC) is one of the most common malignancies in head and neck. Platinum-based chemotherapy is an important treatment for NPC. However, the molecular mechanism of resistance to platinum drug remains unknown. Endopla
Autor:
Xinghao Ai, Ziming Li, Zhiwei Chen, Hong Jian, Zhen Zhou, Zheng-bo Song, Shun Lu, Yongfeng Yu
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
Background Standard therapy for human epidermal growth factor receptor 2 (HER2)-mutant non-small-cell lung cancer (NSCLC) is lacking. The clinical benefits with pan-HER inhibitors (afatinib, neratinib, and dacomitinib), anti-HER2 antibody drug conjug